Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
The Leukemia & Lymphoma Society (LLS) today announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute in Boston; Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center in New York; MD Anderson Cancer Center in Houston; Fondazione Centro San Raffaele in Milan; and South Australian Health & Medical Research Institute in Adelaide.
This $40.3 million investment, comprised of 75 new research grants in LLS’s portfolio of 300 projects, will fund a diverse array of research to find better treatments and cures for patients with leukemia, lymphoma, myeloma and other blood cancers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554855-lls-invests-millions-new-research-treatment-cures/
Ortho Clinical Diagnostics (OCD), in partnership with the National Association of Chronic Disease Directors (NACDD), today unveiled new consumer survey results and a report revealing the state of blood test health literacy in the United States with strategies to support much-needed patient education and empowerment. The first step: ensuring patient access to and understanding of blood test results, a critical component to maintaining health and wellness. The campaign kicks off during National Health Literacy Month, an awareness effort founded in 1999 to promote the importance of understandable health information.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52662-ortho-clinical-diagnostics-and-nacdd-blood-test-health-literacy-survey
FOLLOW!! @Miss_Erica http://www.Twitter.com/Miss_Erica FREE DOWNLOAD http://www.Facebook.com/EricaDiamondsMusic . Lyrics: Ya girl Done took of on em YeP! I done up & Done it . Start investigating I'm the worlds most wanted . But the world I don't want it No it can't do nothing 4 me . So im not eatin what they tryna feed me like'Yummy? ' Like Dummy, Life is more than stackin money . its not a contradiction Its a true statement Honey! Blind 2 the world -i'm Spirit led- Unlike these anorexic Christians I'm spirit Fed . So u can call me Sara Lee I'm in the Bakery . Breakin Bread I got my own Recipe . The Word of God cures sin - its a sad Disease . I can't be around it,excuse me, Bad Allergies . I'm all natural call me organic Lemme break it down so that you can understand it .Born again, New in my own skin, dipped in the blood Im a transfusion ::HOOK:: Make the funeral arrangements my flesh already dead Flesh already dead,Flesh already dead, how did i die It was suicide The Obituary said i killed my flesh & my pride
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received U.S. Food and Drug Administration (FDA) clearance for the ClearSight system.
The ClearSight system is a noninvasive monitor that provides clinicians access to valuable blood volume and blood flow information for patients at moderate or high risk of post-surgical complications, in whom invasive monitoring would not be used.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7256451-edwards-fda-clearance-for-noninvasive-hemodynamic-monitoring-system/
Al-Dura Calls Children to follow him to Paradise Clip PATV 2000-2003 PATV June 28, 2006 "I am waving to you, not in parting, but to say follow me" Muhammad al-Dura How sweet is the fragrance of the martyrs. How sweet is the fragrance of the earth its thirst quenched by the gush of blood flowing from the youthful body How sweet is the fragrance of the martyrs O father, till we meet till we meet O father, till we meet
(more)
Ruby dreams of love and escaping the Congregation. But if Ruby leaves, the Congregation will die without the secret ingredient to the Water, her blood. So she stays, and prays to their savior Otto, who first gave Water to the Congregants, and fathered Ruby before he vanished. Learn more about this book here, http://bit.ly/eqpEJw and its author here, http://www.pambachorz.com YA
Novartis announced today that the US Food and Drug Administration (FDA) has approved Jadenu™ (deferasirox) tablets, a new oral formulation of Exjade® (deferasirox) tablets for oral suspension, for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT) in patients 10 years of age and older. Jadenu is the only once-daily oral iron chelator that can be swallowed whole.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7440151-novartis-jadenu-fda-approval/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
